DE69413829D1 - Antiglucocorticoidsteroide zur behandlung von angststörungen - Google Patents

Antiglucocorticoidsteroide zur behandlung von angststörungen

Info

Publication number
DE69413829D1
DE69413829D1 DE69413829T DE69413829T DE69413829D1 DE 69413829 D1 DE69413829 D1 DE 69413829D1 DE 69413829 T DE69413829 T DE 69413829T DE 69413829 T DE69413829 T DE 69413829T DE 69413829 D1 DE69413829 D1 DE 69413829D1
Authority
DE
Germany
Prior art keywords
pct
anxiety disorders
antiglucocorticoidsteroids
treating anxiety
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69413829T
Other languages
English (en)
Other versions
DE69413829T2 (de
Inventor
Bernardus Wynand Machi Peeters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69413829D1 publication Critical patent/DE69413829D1/de
Publication of DE69413829T2 publication Critical patent/DE69413829T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69413829T 1993-08-04 1994-07-28 Antiglucocorticoidsteroide zur behandlung von angststörungen Expired - Lifetime DE69413829T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93202304 1993-08-04
PCT/EP1994/002513 WO1995004536A1 (en) 1993-08-04 1994-07-28 Antiglucocorticoid steroids for the treatment of anxiety disorders

Publications (2)

Publication Number Publication Date
DE69413829D1 true DE69413829D1 (de) 1998-11-12
DE69413829T2 DE69413829T2 (de) 1999-04-15

Family

ID=8214027

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69413829T Expired - Lifetime DE69413829T2 (de) 1993-08-04 1994-07-28 Antiglucocorticoidsteroide zur behandlung von angststörungen

Country Status (11)

Country Link
US (1) US5741787A (de)
EP (1) EP0712311B1 (de)
JP (1) JP3828926B2 (de)
AT (1) ATE171873T1 (de)
AU (1) AU687088B2 (de)
CA (1) CA2166332C (de)
DE (1) DE69413829T2 (de)
DK (1) DK0712311T3 (de)
ES (1) ES2124905T3 (de)
NZ (1) NZ271363A (de)
WO (1) WO1995004536A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156836T1 (de) * 1994-05-19 1997-08-15 Akzo Nobel Nv 11,21-bisphenyl-19-nor-pregnan derivate
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL119649A (en) * 1995-11-30 2002-03-10 Akzo Nobel Nv Preparation of Cyclic Kills of History - 3 keto- (5) 10, (-9) 11 steroidadians
ES2120267T3 (es) * 1995-12-22 1998-10-16 Jenapharm Gmbh Nuevos derivados de 17alfa-cianometilestra-4,9-dieno, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
HU230492B1 (hu) * 1996-05-01 2016-08-29 The Government Of The United States Of America Új progesztációt gátló szerként használható 21-helyzetben szubsztituált progeszteron-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
EP1079859B1 (de) 1998-05-22 2010-07-14 The Board Of Trustees Of The Leland Stanford Junior University Bifunktionelle moleküle sowie darauf basierende therapien.
ES2230880T3 (es) * 1998-07-30 2005-05-01 Abbott Laboratories Agentes selectivos anti-inflmatorios de glucocorticoides.
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US7250408B2 (en) 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
CA2516319C (en) * 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息***
EP1945240B1 (de) 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Zusammensetzungen mit rezeptor-assoziierten protein (rap) varianten, die für cr-haltige proteine spezifisch sind und ihre verwendungen
PL3395372T3 (pl) 2009-02-20 2022-07-25 EnhanX Biopharm Inc. Układ do dostarczania leków na bazie glutationu
KR20190116576A (ko) 2009-05-06 2019-10-14 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
CA3039636C (en) 2016-10-07 2023-04-11 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series

Also Published As

Publication number Publication date
DK0712311T3 (da) 1999-06-21
ES2124905T3 (es) 1999-02-16
DE69413829T2 (de) 1999-04-15
NZ271363A (en) 1999-06-29
EP0712311B1 (de) 1998-10-07
JP3828926B2 (ja) 2006-10-04
CA2166332C (en) 2005-05-10
WO1995004536A1 (en) 1995-02-16
ATE171873T1 (de) 1998-10-15
AU7496894A (en) 1995-02-28
AU687088B2 (en) 1998-02-19
EP0712311A1 (de) 1996-05-22
CA2166332A1 (en) 1995-02-16
JPH09501172A (ja) 1997-02-04
US5741787A (en) 1998-04-21

Similar Documents

Publication Publication Date Title
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE253892T1 (de) Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
ATE241362T1 (de) Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE172963T1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
ATE346867T1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69838882D1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE69535131D1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
BR0010338A (pt) Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto
ES2123796T3 (es) Derivados de acidos fosfono-succinicos y su utilizacion como medicamentos.
DE59409813D1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

R082 Change of representative

Ref document number: 712311

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE